The likelihood for avoidance of five clinically important outcomes in patients with COPD and type 2 inflammation was greater ...

Dupilumab, a fully human monoclonal antibody, 19,20 blocks the shared receptor component for interleukin-4 and interleukin-13, key and central drivers of type 2 inflammation. 18,21,22 Dupilumab is ...

Since its release in 2017, dupilumab (a fully humanized monoclonal antibody that blocks IL-4 and IL-13) has transformed the therapeutic landscape for managing atopic dermatitis (AD) and other ...

All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...

Researchers compared dupilumab use with other and with no systemic therapy. Dupilumab inhibits IL-4 and IL-13, which have been linked to internal tumorigenesis. Perspective from Raj Chovatiya ...

Antihistamines are often tried, but they usually only work half the time. Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade.

This study enhances current understandings of dupilumab use in patients with atopic dermatitis (AD) by showing its real-world effectiveness and safety. Dupilumab is an effective and safe treatment ...

Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab ...

A randomized placebo-controlled study found the monoclonal antibody dupilumab (Dupixent) led to histologic remission in significantly more affected children than placebo. Data from this trial led ...

In a post-hoc analysis, dupilumab improved symptoms of atopic dermatitis (AD) in young children ages 6 months to 5 years. Youngsters with associated comorbidities such as asthma, allergic rhinitis ...